Reported in this case is epigastric pain that radiates to the thoracolumbar area, but other associated symptoms may include jaundice, diabetes mellitus, and cachexia, among others. Another quite relevant problem that occurs with pancreatic adenocarcinomas is that most of them are unresectable, that is, they cannot be removed by surgery. Only in 20% of cases is it possible to resort to surgery (when the adenocarcinoma is less than 6 cm in size and does not present metastasis or invasion of vascular tissues). Scientists bring out the heavy artillery: new pancreatic cancer treatment fortunately, hope seems not to be entirely lost.
An article was recently published in the new england journal of medicine detailing a new method of immunotherapy to slow down the progression of this cancer. This targeted therapy is based on the fact that pancreatic adenocarcinoma cells have a e commerce photo editing service somatic mutation in the kras proto -oncogene (whose product is largely responsible for tumor formation). This makes them susceptible to uncontrolled division, and is also practically invisible to the immune system, specifically to cytotoxic t cells or cd8 + . In 2020, the researchers who developed the method took a 71-year-old patient with progressive metastatic pancreatic adenocarcinoma who had already undergone other chemotherapy treatments without success.
To carry out this technique, they extracted mononuclear cells from their peripheral blood, which they treated in vitro to produce their differentiation into t cells. Using genetic engineering techniques, these cells were reprogrammed so that the membrane receptor responsible for binding to hla (complex major histocompatibility) to specifically recognize the mutated kras protein of tumor cells. Inesem business school course in antibiotic, immune and antineoplastic pharmacology more information the modified cells were
